Skip Navigation

Multi-arm Phase II Study OF Ubamatamab REGN4018; MUC16�CD3 Bispecific Antibody With or Without Additional Agents in Platinum-resistant Ovarian Cancer

Brief Summary

Type:
Ovarian

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT06787612

Study #:
STUDY00161593

Start Date:
Sep 05, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06787612

View Complete Trial Details & Eligibility at ClinicalTrials.gov